ASCs face increasing delays and denials from payers impacting revenue cycles. Increased scrutiny on device/pharma claims and contract carve-outs prompt ASC contract renegotiations amid Medicare Advantage changes.

Elevance Health outperforms competitors by managing Medicare Advantage costs effectively and driving robust growth in its Carelon segment, bolstering its 2025 outlook and earning a Strong Buy rating with growth potential.